US FDA Stuck With Less Flexibility On Drug Vs. Device Designations After Appeals Court Decision
Executive Summary
Products that seem to meet both drug and device standards will probably now be designated devices after an appeals court concludes that US FDA has less discretion than it has historically exercised.
You may also be interested in...
Ophthalmic Drug Dispensers Being Reclassified In US As Combo Products Get Regulatory Leeway
US FDA gives 12 month grace period for ophthalmic products once regulated as drugs to comply with requirements for combination products and temporarily exempts lower-risk constituents. Guidance specifies changes agency is making in response to Genus Medical v. FDA decision.
Ophthalmic Drug Dispensers Being Reclassified As Combo Products Get Some Regulatory Leeway
US FDA gives 12 month grace period for ophthalmic products once regulated as drugs to comply with requirements for combination products and temporarily exempts lower-risk constituents. Guidance specifies changes agency is making in response to Genus Medical v. FDA decision.
US FDA’s Reclassification Of Certain Drugs As Devices May Be 'Seismic Event' For Some
Sponsors are receiving information requests and complete response letters as a result of the agency’s transition plan, which was made in response to the Genus v. FDA ruling. The decision's aftershocks could reshape the landscape for a number of products, attorney says.